Drugs / tirasemtiv

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 26 trials
Phase 2 NCT01709149 Oct 2012 → Mar 2014 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded
Phase 2 NCT01486849 Nov 2011 → Mar 2012 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded
Phase 2 NCT01378676 Jun 2011 → Mar 2012 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded
Phase 2 NCT01268280 Dec 2010 → Oct 2012 generalized myasthenia gravis Cytokinetics Terminated No outcome recorded
Phase 2 NCT01131013 May 2010 → Mar 2011 intermittent vascular claudication, peripheral arterial disease Cytokinetics Completed No outcome recorded
Phase 2 NCT01089010 Mar → Nov 2010 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02936635 Oct 2016 → Oct 2018 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded
Phase 3 NCT02496767 Sep 2015 → Mar 2017 amyotrophic lateral sclerosis Cytokinetics Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as tirasemtiv ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496767
1

NCT02936635

Known as CK-2017357 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01131013
5

NCT01486849

NCT01378676

NCT01709149

NCT01089010

NCT01268280

Action Activate “a novel small-molecule activator of the fast skeletal muscle troponin complex” PMID 24872402 May 2014
Modality Other / unclassified “CK-2017357, an orally bioavailable fast skeletal muscle troponin activator” PMID 22591195 May 2012
Route Oral “250 mg CK-2017357 in capsules administered as a single oral dose.” NCT01089010